XCMR secures a patent for a groundbreaking protective respirator that utilizes Far UV-C radiation to inactivate airborne pathogens.
PHILADELPHIA, PA—October 24, 2023: XCMR Inc., a medtech company that develops proprietary UV-C technology to prevent the transmission of infectious diseases, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,793,904 for its groundbreaking protective respirator technology. This patent recognizes XCMR’s unique approach to respiratory protection, which uses Far UV-C radiation to inactivate pathogens in real time, offering a new level of safety and efficacy.
The patented respirator employs Far UV-C light, specifically around 222 nanometers in wavelength, to create a “kill zone” in front of the user’s mouth and nose. This kill zone effectively neutralizes airborne pathogens, including viruses and bacteria, before they can be inhaled, providing superior protection compared to traditional filtration-based masks.
“This patent is a significant milestone for XCMR and validates our commitment to developing cutting-edge solutions for Near-field Infection Protection,” said XCMR CEO Richard Rasansky. “Our Far UV-C respirator technology has the potential to revolutionize respiratory protection, offering enhanced safety, comfort, and adaptability to a wide range of environments and threats.”
XCMR’s Far UV-C respirator technology has broad applications across various industries, including healthcare, industrial settings, and public spaces. The company is actively exploring partnerships and collaborations to bring this innovative solution to market and make a meaningful impact on public health and safety.
XCMR is a medtech company dedicated to transforming personal protection from infectious diseases through innovative UV-C technologies. Backed by rigorous scientific testing, XCMR’s solutions provide continuous disinfection of air and surfaces. This innovative approach extends to wearable, portable, and stationary devices to provide a protective “safe zone” of cleansed air, enhancing infection prevention, and addressing antimicrobial resistance concerns. Our patented maskless approach, powered by Near-field Infection Protection (NIP™) technology, creates a biosafety barrier against aerosol transmission in close-contact environments. XCMR’s next-generation implementation of UV-C demonstrates radical innovation as a medical countermeasure against disease by delivering clean air to one’s personal space. To learn more about XCMR’s commitment to providing a healthier and safer future for all, especially our most vulnerable populations, visit xcmr.co.
